25,994 research outputs found
Author Peter FitzSimons speaking at the National Library of Australia, Canberra, 13 November 2012 /
No full textTitle from acquisitions documentation.; Part of the collection: Portraits of author Peter FitzSimons speaking at the National Library of Australia, Canberra, 13 November 2012.; Acquired in digital format; access copy available online.; Mode of access: Online.; Photographed by a staff member of the National Library of Australia
The third International Stroke Trial (IST-3)
No full textThe IST-3 trial is a large-scale randomised controlled trial of intravenous thrombolytic therapy of the drug Alteplase for patients with acute ischaemic stroke. The dataset includes a number of files describing the IST-3 dataset. The documentation files may be freely downloaded. The raw patient-level data files were under embargo until the 25th of January 2021 (“datashare_aug2015.sas7bdat” or “ist3.dat”); since that embargo has expired, it is no longer necessary to apply to the study investigators for access.
***
The IST3 has an international trials registry ID number, which enables all the trials outputs to be linked: ISRCTN25765518
https://doi.org/10.1186/ISRCTN2576551
Moral Good, the Beatific Vision, and God’s Kingdom Writings by Germain Grisez and Peter Ryan, S.J.. Edited by Peter J. Weigel
No full textFor close to half a century, the work of Germain Grisez has been highly influential, and his writings continue to receive considerable attention from philosophers and theologians of diverse viewpoints. His co-author for this work is the professor and noted moral theologian Fr. Peter Ryan, S.J., currently the executive director of the Secretariat of Doctrine and Canonical Affairs of the United States Conference of Catholic Bishops (USCCB). These two eminent scholars explore fundamental questions about Christian eschatology, moral theory, the purpose of human life, and the promise of human fulfilment. The authors examine Christian teaching on the final destiny of persons, investigating the meaning of God's kingdom, the hope of the beatific vision, and the centrality of moral goodness and divine grace in one's final end. This work is an ideal source for students, scholars, ministers and lay persons interested in basic questions of Christian theology, the philosophy of religion, ethical theory, and Catholic doctrin
Murder on the mountain: author talk with Peter J. Wosh
No full textAuthor talk by Peter J. Wosh on May 5th, 2022, on his book, "Murder on the Mountain: crime, passion, and punishment in gilded age New Jersey.
Supplemental material for Top 10 global educational topics in stroke: A survey by the World Stroke Organization
No full textSupplemental Material for Top 10 global educational topics in stroke: A survey by the World Stroke Organization by Monica Saini, Sarah Belson, Carmen Lahiff-Jenkins and Peter Sandercock in International Journal of Stroke</p
Updated bibliography for the IST-3 study
No full textThis is a bibliography of publications from the IST-3 trial (International Stroke Trial).
This fileset comprises two files containing the same bibliography in different formats (Word and PDF-A respectively), for accessibility. This dataset provides additional documentation for the previously-deposited dataset which contained data from the clinical trial:
Sandercock, P; Wardlaw, J; Lindley, R; Cohen, G; Whiteley, W. (2016). "The third International Stroke Trial (IST-3)", 2000-2015 [dataset]. University of Edinburgh & Edinburgh Clinical Trials Unit. https://doi.org/10.7488/ds/135
Lunchtime Talk with Author and Attorney Peter Godwin
No full textAuthor and attorney Peter Godwin gave a lunchtime talk about the topics discussed in his book, The Fear, which focuses on the human rights situation in Zimbabwe under the rule of Robert Mugabe
Blood markers for the diagnosis and prognosis of stroke
No full textMany blood markers have been associated with stroke. I set out to determine
whether blood markers can be applied to: (i) improve the accuracy of the clinical
diagnosis of stroke or TIA, and/or (ii) improve the prediction of poor outcome in
patients who are still symptomatic at the time of admission with stroke or TIA.
I systematically reviewed the existing literature on the diagnostic performance of a
range of blood markers measured soon after stroke onset, to inform the choice of
markers for my subsequent prospective studies in this thesis. Many studies had
deficiencies in their design, which may have explained the apparently – and
perhaps spuriously - impressive diagnostic performance of several markers. In the
light of these data I was able to improve the design of my own studies and suggest
how future studies of diagnostic markers could be improved.
In order to define an appropriate comparator test for assessing the diagnostic
accuracy of blood markers, I first examined the performance of emergency room
nurses and doctors. I assessed the accuracy of their diagnosis of TIA or stroke
(‘acute cerebrovascular disease’) in patients presenting with symptoms of suspected
stroke, and compared them with a number of stroke diagnostic scales. In the 405
patients recruited to the study, the sensitivity of emergency department staff was
77% and specificity 58%. Each stroke diagnostic scale had a slightly better
sensitivity, though worse specificity, than an emergency department clinician. I
decided to use the diagnosis by an emergency department clinician of ‘probable or
definite acute cerebrovascular disease’ as the best clinical performance reference
standard.
In blood taken from the same cohort of 405 patients, accredited research laboratories
measured markers of inflammation, thrombosis, thrombolysis, cardiac strain and
cerebral damage. Tissue plasminogen activator and loge N-terminal pro brain
natriuretic peptide were associated positively with a diagnosis of acute cerebrovascular disease, though each marker did not add diagnostic value to the
diagnosis of an emergency department doctor or nurse.
I systematically reviewed the literature examining the association between the levels
of blood markers with poor outcome (i.e. death or dependency) after stroke. I found
that although almost all markers studied had a positive association with poor
outcome, there were methodological problems with many studies, chiefly small
sample size, publication bias or within study reporting biases, and lack of
adjustment for important confounders such as age or stroke severity.
With data from the Edinburgh Stroke Study, I examined the association between
circulating markers of the inflammatory response (white cell count, interleukin-6, Creactive
protein and fibrinogen) and poor outcome after stroke. After adjustment for
age, whether the patient lived alone, was independent of activities of daily living,
was orientated, able to lift both arms and able to walk, I found that higher levels of
interleukin-6, white cell count and glucose were associated with poor outcome. The
relevant test of a biological marker is not its predictive ability alone, but whether,
when added to a validated predictive model based on clinical variables, it improves
the prediction of outcome. No individual marker improved the prediction of poor
outcome when added to a validated prognostic model based on clinical variables
alone.
From my cohort of 405 patients with suspected stroke 285 patients had a confirmed
diagnosis. Follow up of these 285 patients with confirmed acute cerebrovascular
disease showed that, after adjustment for neurological impairment and age, only
interleukin-6 and N-terminal pro brain natriuretic peptide were significantly
associated with death or disability at 3 months. Neither marker improved the
predictions of a model to predict poor outcome based on clinical variables alone.
To examine the relationship between circulating markers of the inflammatory
response and recurrent stroke, myocardial infarction, and vascular death (‘recurrent
vascular events’), again I used data from the Edinburgh Stroke Study. After adjustment for clinical predictors (age, prior MI, stroke, or TIA and AF) I found that
higher levels of interleukin-6, C-reactive protein and fibrinogen remained
significantly associated with an increased risk of recurrent vascular events.
However, the relationship with deaths from all causes was somewhat stronger for
each marker, perhaps suggesting that higher marker levels were associated with
debility rather than vascular events per se.
In conclusion, I found no marker measured could improve on the diagnostic
accuracy of an emergency department clinician for acute cerebrovascular disease,
nor improve the prediction of poor outcome by a prognostic model based upon
clinical variables. The work of this thesis does not support the routine use of blood
markers as an aid to the diagnosis of, or the prediction of outcome of, acute stroke
An essay about the Francis Paudras Collection on Bud Powell by Peter Pullman
No full textThis is an essay about the Francis Paudras Collection on Bud Powell written by Peter Pullman, a jazz scholar and author of Wail: The Life of Bud Powell (Brooklyn: Bop Changes, 2012).One image file (pdf)This project was supported by a Recordings at Risk grant from the Council on Library and Information Resources (CLIR). The grant program is made possible by funding from The Andrew W. Mellon Foundation
Professor Peter Singer speaking at the National Press Club Canberra, 11 February 2009 [picture] /
No full textTitle devised by cataloguer based on information from acquisitions documentation.; Part of the collection: Humanitarian author Professor Peter Singer at the National Press Club, Canberra, 11 February 2009.; Acquired in digital format; access copy available online.; Mode of access: Internet via World Wide Web.; Photographed by a staff member of the National Library of Australia, 2009
- …
